Daily Roundup

Wednesday, 18th November 2026 · updated 18:00

Tasmea on a Roll with Second Guidance Upgrade

Tasmea Limited is riding high after delivering a record first quarter, prompting the company to upgrade its FY27 earnings guidance for the second time. The specialist services provider now expects underlying EBITA of A$210-215 million and underlying NPATA of A$133-136 million, buoyed by organic growth exceeding 15%. Recent acquisitions of Maxim Group and JPS Group are also punching above their weight, contributing meaningfully to the strong performance. With a fresh A$250 million undrawn debt facility in the back pocket, Tasmea appears well-positioned to capitalize on elevated demand across its diversified portfolio.

The company's momentum is particularly impressive given FY26 already delivered exceptional results, with underlying EBITA surging 54% to A$118.1 million and revenue nearly doubling to A$1.3 billion. Underlying NPATA climbed 43% to A$73.7 million, while earnings per share grew 27% to 28.8 cents. The Board rewarded shareholders with a fully franked dividend of 24.5 cents per share, up 32% from the prior year.

EML Payments Holding Steady Despite Revenue Dip

EML Payments Ltd reported Q1 FY27 trading in line with forecasts, though the quarter wasn't without headwinds. Revenue slipped 3% to A$46.2 million, while gross profit dipped 4% to A$33.7 million. However, the company managed to trim net overheads by 6% to A$26.6 million, and underlying EBITDA actually ticked up 6% to A$7.1 million.

The real bright spot? EML achieved a perfect 100% renewal rate on its top 30 contracts, signaling strong client retention despite the softer top-line performance. The company reaffirmed its FY27 underlying EBITDA guidance of A$50-54 million and is making solid progress on Project Arlo. Management is targeting a commercial pipeline exceeding A$150 million by June 2027, suggesting better days could be ahead.

Microba-GSS Merger Falls Apart

The proposed merger between Microba Life Sciences and Genetic Signatures has officially collapsed. Microba lacked the financial firepower to complete the deal after revised terms made it impossible to meet the conditions of its institutional placement announced in October. Genetic Signatures ultimately decided against providing unsecured debt funding to bridge the gap, citing associated risks and potential regulatory headaches.

Both companies now face an uncertain path forward. Microba remains in voluntary suspension while exploring alternative funding options, leaving investors in limbo about the biotech company's future direction.

New Hope Scores Big with Hybrid Securities Offer

New Hope Corporation successfully completed a bookbuild for perpetual step-up hybrid securities, with investor demand so strong the company nearly doubled the offer size to A$500 million from the initial A$250 million target. The margin was set at 4.00% per annum. A replacement prospectus will hit the ASX on 24 November, with the offer opening that same day and closing on 9 December. The robust demand underscores positive investor sentiment toward the mining company.

Cettire Flexing Profitability Muscles

Luxury e-commerce platform Cettire delivered a solid performance for the four months ended 31 October, with gross revenue climbing 18% to A$331.0 million and sales revenue up 15% to A$246.2 million. The delivered margin expanded to 17.1%, while adjusted EBITDA jumped to A$6.9 million, a A$2.3 million improvement. Active customers grew 3% to around 650,000, and the company is sitting pretty with A$27 million in cash and zero debt. Management expects profitability to continue into Q2 despite market uncertainties, with a focus on geographic diversification to fuel future growth.

References